Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites

(1) Backgrounds and aim: Tolvaptan, a selective vasopressin type 2 receptor antagonist, was approved for ascites, and its short-term efficacy and safety have been confirmed. However, it is still unclear whether this novel drug may improve long-term survival rates in cirrhotic patients with ascites....

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:J Clin Med
Main Authors: Hosui, Atsushi, Tanimoto, Takafumi, Okahara, Toru, Ashida, Munehiro, Ohnishi, Kohsaku, Wakahara, Yuhhei, Kusumoto, Yukihiro, Yamaguchi, Toshio, Sueyoshi, Yuka, Hirao, Motohiro, Yamada, Takuya, Hiramatsu, Naoki
Formáid: Artigo
Teanga:Inglês
Foilsithe: MDPI 2021
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7830941/
https://ncbi.nlm.nih.gov/pubmed/33466878
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm10020294
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla